Contraception, Female.
Emergency contraception - Postcoital contraception.
Menorrhagia.

Levonorgestrel is a synthetic and biologically active progestogen that inhibits ovulation or fertilization via alteration of tubal transport of sperm and/or ova and thickening the cervical mucus. It also inhibits implantation via alteration of the endometrium .

Distribution:
Vd: 1.8 L/kg
Metabolism:
Serum/Plasma: Extent unknown, via conjugation
Liver: Extent unknown, primarily via CYP3A4
Substrate of CYP450 enzymes, especially CYP3A4
Excretion:
Renal: 45% changed and unchanged

Acute liver disease or liver tumor (benign or malignant)
Acute or history of pelvic inflammatory disease or active endometritis, unless there has been a subsequent intrauterine pregnancy
Breast carcinoma , known or suspected, current or history of
Conditions associated with increased susceptibility to infections (eg, leukemia, AIDS, IV drug abuse) , including pelvic infection
Congenital or acquired uterine anomaly, including fibroids, that distorts the uterine cavity and would be incompatible with correct intrauterine contraceptive system (IUS) placement
Genital bleeding of unknown etiology
Hypersensitivity to any component of the product
Intrauterine device that has not been removed
Known or suspected hormone-sensitive cancer, current or history of
Known or suspected uterine or cervical neoplasia , or unresolved, abnormal Pap smear
Infected abortion in the past 3 months
Pregnancy, known or suspected
Thrombophlebitis or thromboembolic disorders (current)
Untreated cervicitis or vaginitis, including bacterial vaginosis or other lower genital-tract infections, until infection is controlled
Use of intrauterine system as post-coital (emergency) contraception
Uterine bleeding of unknown etiology

Fetal risk has been demonstrated. (TH)

Infant risk cannot be ruled out.(MDX)

Common:
Dermatologic: Acne (6.8% to 14.5% )
Gastrointestinal: Abdominal pain (12.7% to 13.3% ), Nausea (Intrauterine route, up to 9.4% ; oral route, 13.7% ; subdermal route, 11.6% )
Neurologic: Dizziness (9.6% to 14.5% ), Headache (Intrauterine route, 8.7% to 12.9% ; oral route, 10.3% ; subdermal route, 30.5% ), Migraine (Intrauterine route, 2.3% to 3.3% )
Reproductive: Abnormal vaginal bleeding (1% to 57% ), Amenorrhea (Mirena(R), 18.4% ; Skyla(TM), up to 12% ; Kyleena(TM), up to 23% ; Liletta(TM), up to 38% ; Jadelle(R), 7.9% to 12.3% ), Bleeding between periods (Mirena(R), 31.9% ), Breast tenderness (Intrauterine route, 3.3% to 3.5% ; oral route, 8.2% ), Discharge from female genitalia (Mirena(R), 14.9% ; Kyleena(TM), 4.5% Skyla(TM), 4.2% ; Liletta(R), 5.3% ; Jadelle(R) subdermal, 30.3% ), Dysmenorrhea (5.6% to 8.6% ), Hypomenorrhea (Mirena(R), 23.4% ; subdermal, 1.7% to 2.6% ), Menorrhagia (Oral route, 30.9% ; subdermal route, 1.4% to 27% ; intrauterine route, 7.9% to 11.9% ), Pain in female pelvis (Intrauterine route, 6.2% to 8.2% ; subdermal route, 24.4% ), Pain of breast (Intrauterine route, 7.1% to 8.5% ), Vaginitis (16.3% ), Vulvovaginitis (Intrauterine route, 10.5% to 24.3% )
Other: Fatigue (13.3% )
Serious:
Cardiovascular: Myocardial infarction
Dermatologic: Implant site reaction
Endocrine metabolic: Breast cancer
Gastrointestinal: Cholecystitis
Hematologic: Deep venous thrombosis, Venous thrombosis
Hepatic: Cholelithiasis, Cholestatic jaundice syndrome
Neurologic: Idiopathic intracranial hypotension (Rare ), Thrombotic stroke
Ophthalmic: Thrombosis of retinal vein
Psychiatric: Depressed mood (Intrauterine route, 0.2% to 0.5% ), Suicidal
Reproductive: Actinomycotic infection, Cyst of ovary (Liletta(TM), 4.3% ; Skyla(TM), 13.2% ; Kyleena(TM), 22.2% ),
Ectopic pregnancy (Intrauterine route, 0.1 to 0.6% per year ), Expulsion intrauterine contraceptive device (Intrauterine route, 3.2% to less than 5% ), Miscarriage (Kyleena(TM), 0.2% ), Pelvic inflammatory disease (Intrauterine route, 0.4% to 0.5% ), Uterine perforation by intrauterine contraceptive device (Intrauterine route, less than 0.1% )
Respiratory: Pulmonary embolism
Other: Sepsis

在月經開始的7天內，或在第一孕期流產或小產後立即，或在第二孕期流產或小產或分娩後至少6週且子宮完全恢復正常後，將一個52毫克系統置入子宮內，無需使用備用避孕措施。

Insert a 52 mg system intrauterinely within 7 days of the onset of menstruation, immediately after first-trimester abortion or miscarriage, or after a minimum of 6 weeks following second-trimester abortion, miscarriage, or childbirth, once the uterus has fully involuted, without the need for backup contraception.

避孕之療效可長達8年；治療月經過多和預防雌激素補充治療引起的子宮內膜增生兩者療效則最長5年。

The contraceptive efficacy can last up to 8 years; the efficacy for both treating heavy menstrual bleeding and preventing endometrial hyperplasia caused by estrogen replacement therapy lasts up to 5 years. <2024/9/13>